Roger W. Li

Oncology
12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 221 publications

Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.

Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.

Journal: Nature reviews. Urology
Published: July 22, 2026

Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications.

Histological Subtypes of Bladder Cancer: Epidemiology, Molecular Biology, and Clinical Implications.

Journal: Cancers
Published: May 31, 2026

Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.

Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.

Journal: Urologic oncology
Published: May 18, 2026

Clinical Outcomes in Bacillus Calmette-Guérin-Exposed Non-Muscle-Invasive Bladder Cancer.

Clinical Outcomes in Bacillus Calmette-Guérin-Exposed Non-Muscle-Invasive Bladder Cancer.

Journal: JAMA network open
Published: April 16, 2026

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.

Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer.

Journal: Journal for immunotherapy of cancer
Published: April 15, 2026

Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.

Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.

Journal: Nature reviews. Urology
Published: March 11, 2026

Bacillus Calmette-Guérin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naïve Non-Muscle-Invasive Bladder Cancer Progress or Overreach?

Bacillus Calmette-Guérin (BCG) and Beyond: Is Systemic Immunotherapy for BCG-Naïve Non-Muscle-Invasive Bladder Cancer Progress or Overreach?

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 02, 2026

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications.

Journal: European urology
Published: February 20, 2026

Less Is More? How Much Bacillus Calmette-Guérin (BCG) Is Enough for BCG-naïve High-risk Non-muscle invasive Bladder Cancer?

Less Is More? How Much Bacillus Calmette-Guérin (BCG) Is Enough for BCG-naïve High-risk Non-muscle invasive Bladder Cancer?

Journal: European urology
Published: January 21, 2026

Predictors and Patterns of Nonurothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration): Erratum.

Predictors and Patterns of Nonurothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration): Erratum.

Journal: The Journal of urology
Published: January 09, 2026

Recent advances in liquid biopsy for genitourinary cancers: A narrative review.

Recent advances in liquid biopsy for genitourinary cancers: A narrative review.

Journal: Histopathology
Published: December 12, 2025

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

Journal: The Lancet. Oncology
Published: December 12, 2025
Showing 1-12 of 221

Last Updated: 09/26/2026